A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399)Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, LocallyAdvanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Project: Research project

Project Details

Description

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
StatusActive
Effective start/end date11/6/2311/30/33

Funding

  • ABBVIE INC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.